Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β2-agonists in Patients with Moderate to Severe Asthma: A Randomized, Controlled Study

被引:3
|
作者
Wang, Yan [1 ]
Chen, Ping [2 ]
Dai, Anna [1 ]
Shang, Shengyun [1 ]
Kong, Lingfei [1 ]
机构
[1] China Med Univ, Hosp 1, Inst Resp Dis, 155 Nanjing North St, Shenyang 110001, Liaoning Provin, Peoples R China
[2] Gen Hosp Shenyang Mil Reg, Resp Med, Shenyang, Liaoning, Peoples R China
关键词
fluticasone aerosol; moderate to severe persistent asthma; salmeterol/fluticasone propionate aerosol; theophylline tablets; treatment; PERSISTENT ASTHMA; LUNG-FUNCTION; BUDESONIDE; THERAPY; MONTELUKAST;
D O I
10.1016/j.clinthera.2016.10.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol. Methods: After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/ fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment. The main outcome measurements were forced expiratory volume in 1 second and fractional concentration of exhaled nitric oxide value, whereas the secondary measures were forced vital capacity, peak expiratory flow value, and Asthma Control Test/Asthma Quality of Life Questionnaire score. Findings: Forty-four cases completed the course, with 23 cases in the experiment group and 21 cases in the control group. The forced expiratory volume in 1 second values of both groups were significantly improved from before (P < 0.05). The fractional concentration of exhaled nitric oxide values of both groups were significantly decreased from before (P < 0.05). The secondary outcome measurements after treatment achieved obvious improvement from baseline (P < 0.05) in both. There was no significant difference between the 2 groups in all measurements. In addition, the blood biochemistry results, ECG results, and vital signs of both groups had no significant abnormality. Implications: There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:2622 / 2627
页数:6
相关论文
共 50 条
  • [31] Long-acting β2-agonists in the management of asthma exacerbations
    Hospenthal, MAC
    Peters, JI
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (01) : 69 - 73
  • [32] Safety Profile of long-acting β2-Agonists in Asthma
    Rukavina, Marion
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (18) : 1290 - 1290
  • [33] An update on the safety of long-acting β-agonists in asthma patients using inhaled corticosteroids
    Salpeter, Shelley R.
    EXPERT OPINION ON DRUG SAFETY, 2010, 9 (03) : 407 - 419
  • [34] Combined analysis of asthma safety trials of long-acting β2-agonists
    Teper, Alejandro
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2019, 117 (01): : E84 - E86
  • [35] Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists
    Busse, William W.
    Bateman, Eric D.
    Caplan, Arthur L.
    Kelly, H. William
    O'Byrne, Paul M.
    Rabe, Klaus F.
    Chinchilli, Vernon M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2497 - 2505
  • [36] Evaluating the effects of "triple therapy" with inhaled corticosteroids, long-acting β2-agonists, and leukotriene modifiers in asthma
    Currie, Graeme P.
    Lee, Daniel K. C.
    Menzies, Daniel
    Lipworth, Brian J.
    CHEST, 2006, 130 (01) : 301 - 302
  • [37] Benefits of long-acting β2-agonists
    Lipworth, Brian J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (03) : 725 - 725
  • [38] Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma
    Buhl, Roland
    FitzGerald, J. Mark
    Busse, William W.
    RESPIRATORY MEDICINE, 2018, 143 : 82 - 90
  • [39] Pharmacogenomics of long-acting β2-agonists
    Blake, Kathryn
    Lima, John
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (11) : 1733 - 1751
  • [40] New long-acting β2-agonists
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (09) : 1385 - 1388